Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.

Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K, Craddock C, De Santo C.

Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32028. [Epub ahead of print]

PMID:
30485425
2.

NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.

Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C.

PLoS One. 2012;7(2):e32165. doi: 10.1371/journal.pone.0032165. Epub 2012 Feb 27.

3.

MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.

Bao L, Dunham K, Lucas K.

Cancer Immunol Immunother. 2011 Sep;60(9):1299-307. doi: 10.1007/s00262-011-1037-z. Epub 2011 May 28.

PMID:
21626030
4.

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.

Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Blagitko-Dorfs N, Ford LA, Naqash R, Lübbert M, Karpf AR, Nemeth MJ, Griffiths EA.

Oncotarget. 2016 Mar 15;7(11):12840-56. doi: 10.18632/oncotarget.7326.

5.

The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.

Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, Lübbert M.

Leuk Res. 2010 Jul;34(7):899-905. doi: 10.1016/j.leukres.2010.02.004. Epub 2010 Apr 10.

PMID:
20381863
6.

Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.

Klar AS, Gopinadh J, Kleber S, Wadle A, Renner C.

PLoS One. 2015 Oct 8;10(10):e0139221. doi: 10.1371/journal.pone.0139221. eCollection 2015.

7.

5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.

Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M.

Clin Cancer Res. 2002 Aug;8(8):2690-5.

8.

NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.

Bolli M, Schultz-Thater E, Zajac P, Guller U, Feder C, Sanguedolce F, Carafa V, Terracciano L, Hudolin T, Spagnoli GC, Tornillo L.

Int J Cancer. 2005 Jul 20;115(6):960-6.

9.

NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.

Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, Lutgen-Dunckley LG, Martens BL, Odunsi K, Karpf AR, Hourigan CS, Nemeth MJ.

Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. doi: 10.1158/1078-0432.CCR-17-1792. Epub 2017 Sep 25.

10.

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.

PLoS One. 2016 Dec 1;11(12):e0166891. doi: 10.1371/journal.pone.0166891. eCollection 2016. Erratum in: PLoS One. 2017 Feb 15;12 (2):e0172640.

11.

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.

Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, Qureshi A, Dazzi F, Vyas P, Cerundolo V.

Blood. 2013 Aug 1;122(5):749-58. doi: 10.1182/blood-2013-01-480129. Epub 2013 Jun 3.

12.

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, Ng M, Kearns P, Cheng P, De Santo C.

Blood. 2015 Apr 9;125(15):2386-96. doi: 10.1182/blood-2014-09-600643. Epub 2015 Feb 20.

13.

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E.

Br J Haematol. 2013 May;161(3):389-401. doi: 10.1111/bjh.12282. Epub 2013 Feb 25. Erratum in: Br J Haematol. 2013 Aug;162(3):428.

PMID:
23432359
14.

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.

Schneider D, Xiong Y, Hu P, Wu D, Chen W, Ying T, Zhu Z, Dimitrov DS, Dropulic B, Orentas RJ.

Front Oncol. 2018 Nov 22;8:539. doi: 10.3389/fonc.2018.00539. eCollection 2018.

15.

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.

Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P, Karpf AR, Griffiths EA.

Epigenetics. 2015;10(3):237-46. doi: 10.1080/15592294.2015.1017198.

17.

Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells.

Ozkazanc D, Yoyen-Ermis D, Tavukcuoglu E, Buyukasik Y, Esendagli G.

Immunology. 2016 Dec;149(4):460-471. doi: 10.1111/imm.12665. Epub 2016 Sep 29.

18.

A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.

Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S.

Thyroid. 2014 Aug;24(8):1241-50. doi: 10.1089/thy.2013.0680. Epub 2014 Jun 30.

19.

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C.

Blood. 2010 Sep 16;116(11):1908-18. doi: 10.1182/blood-2009-11-249474. Epub 2010 Jun 8.

Supplemental Content

Support Center